Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease-Reference-Cited by-同舟云学术

Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease

Published:2009-09 Issue:3 Volume:51 Page:548-556
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Nozaki Yuichi,Fujita Koji,Yoneda Masato,Wada Koichiro,Shinohara Yoshiyasu,Takahashi Hirokazu,Kirikoshi Hiroyuki,Inamori Masahiko,Kubota Kensuke,Saito Satoru,Mizoue Tetsuya,Masaki Naohiko,Nagashima Yoji,Terauchi Yasuo,Nakajima Atsushi

Publisher

Elsevier BV

Subject

Hepatology

Reference23 articles.

1. Nonalcoholic fatty liver disease as a complication of insulin resistance;Abdelmalek;Med Clin North Am,2007

2. Effect of a multifactorial intervention on mortality in type 2 diabetes;Gaede;N Engl J Med,2008

3. Combination therapy for treatment or prevention of atherosclerosis;Koh;Hypertension,2008

4. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study;Athyros;Curr Med Res Opin,2006

5. Niemann–Pick C1 Like 1 protein is critical for intestinal cholesterol absorption;Altmann;Science,2004

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The molecular mechanisms of peptidyl-prolyl cis/trans isomerase Pin1 and its relevance to kidney disease;Frontiers in Pharmacology;2024-04-22

2. Systems genetics approach uncovers associations between host amylase locus, gut microbiome and metabolic traits in hyperlipidemic mice;2024-03-03

3. Berberine prevents NAFLD and HCC by modulating metabolic disorders;Pharmacology & Therapeutics;2024-02

4. Roux-en-Y gastric bypass induces hepatic transcriptomic signatures and plasma metabolite changes indicative of improved cholesterol homeostasis;Journal of Hepatology;2023-10

5. Intestinal Pgc1α ablation protects from liver steatosis and fibrosis;JHEP Reports;2023-07